269 related articles for article (PubMed ID: 9450562)
21. Refractory acute promyelocytic leukemia with PLZF/RARa rearrangement: a case report and literature review.
Duan X; Liu B; Yang M
Anticancer Drugs; 2023 Jun; 34(5):690-694. PubMed ID: 36729983
[TBL] [Abstract][Full Text] [Related]
22. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
23. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacological and clinical properties of arsenic trioxide (Trisenox) for relapse or refractory acute promyelocytic leukemia therapy].
Tajima M
Nihon Yakurigaku Zasshi; 2005 Jun; 125(6):389-96. PubMed ID: 16079563
[No Abstract] [Full Text] [Related]
25. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Iland HJ; Wei A; Seymour JF
Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
[TBL] [Abstract][Full Text] [Related]
26. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
27. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
28. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
Jing Y; Wang L; Xia L; Chen GQ; Chen Z; Miller WH; Waxman S
Blood; 2001 Jan; 97(1):264-9. PubMed ID: 11133770
[TBL] [Abstract][Full Text] [Related]
29. Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.
Mikoshiba M; Ohashi K; Takei N; Okuyama Y; Maeda Y; Hiruma K; Akiyama H; Fukuhara O; Takeshita A; Sakamaki H
Int J Hematol; 2002 Jan; 75(1):104-6. PubMed ID: 11843281
[No Abstract] [Full Text] [Related]
30. Arsenic trioxide mechanisms of action--looking beyond acute promyelocytic leukemia.
Carney DA
Leuk Lymphoma; 2008 Oct; 49(10):1846-51. PubMed ID: 18949607
[No Abstract] [Full Text] [Related]
31. Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid.
Singh C; Saini M; Jain A; Lad D; Prakash G; Khadwal A; Naseem S; Malhotra P
Blood Cancer J; 2024 Jan; 14(1):14. PubMed ID: 38238308
[No Abstract] [Full Text] [Related]
32. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
33. Treatment of acute promyelocytic leukemia with arsenic trioxide.
Tamm I; Paternostro G; Zapata JM
N Engl J Med; 1999 Apr; 340(13):1043; author reply 1044-5. PubMed ID: 10189285
[No Abstract] [Full Text] [Related]
34. Treatment of acute promyelocytic leukemia.
Miura Y; Suyama K; Takano T
N Engl J Med; 2013 Oct; 369(15):1471-2. PubMed ID: 24106949
[No Abstract] [Full Text] [Related]
35. Treatment of acute promyelocytic leukemia.
Lo-Coco F; Orlando SM; Platzbecker U
N Engl J Med; 2013 Oct; 369(15):1472. PubMed ID: 24106948
[No Abstract] [Full Text] [Related]
36. [Arsenic trioxide, a new drug for the treatment of acute promyelocytic leukemia resistant to tretinoine].
Haanen C; Vermes I
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1738-41. PubMed ID: 10494320
[TBL] [Abstract][Full Text] [Related]
37. [Arsenic treatment for leukemia: new model of human cancer target treatment].
Zhao WW; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):439-40. PubMed ID: 15854545
[No Abstract] [Full Text] [Related]
38. Arsenic: a new place?
Vincent PC
Pathology; 1999 May; 31(2):81-2. PubMed ID: 10399159
[No Abstract] [Full Text] [Related]
39. Newly diagnosed acute promyelocytic leukemia: arsenic moves front and center.
Estey EH; Hutchinson F
J Clin Oncol; 2011 Jul; 29(20):2743-6. PubMed ID: 21646610
[No Abstract] [Full Text] [Related]
40. Higher than normal mitochondrial DNA content associated with better outcome in acute promyelocytic leukaemia? Maybe.
Wiernik PH
Br J Haematol; 2023 Jan; 200(2):126-127. PubMed ID: 36342482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
